Genmab A/S
GMAB- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001434265
No open-market purchases or sales by Genmab A/S insiders were filed in the last 90 days; 291 institutions reported holding it in 13F filings for Q2 2026, worth $2.81B in total; no superinvestor holds it.
Other share classesGNMSF
Q3 2025 vs. Q2 2025
How the institutions holding Genmab A/S changed between Q2 2025 and Q3 2025.
All holders in Q3 2025All holders in Q2 2025
| Measure | Q2 2025 | Of which not filed for Q3 2025 | Q3 2025 | Change |
|---|---|---|---|---|
| Holders | 218 | 3 | 253 | +38 |
| Shares | 63.7M | 72.4K | 61.8M | −1.84M (−2.9%) |
| Value | $1.32B | $1.50M | $1.89B | +$576.4M (+43.9%) |
3 institutions that held it in Q2 2025 haven't filed for Q3 2025 yet. Not filing isn't selling, so the changes leave them out.
New holders (66)
Institutions that held Genmab A/S at the end of Q3 2025 but not at the end of Q2 2025.
Sold out (28)
Institutions that held Genmab A/S at the end of Q2 2025 and filed for Q3 2025 without it.
Not filed for Q3 2025 yet (3)
Institutions that held Genmab A/S at the end of Q2 2025 and haven't filed a 13F for Q3 2025. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2025 | Value, Q2 2025 |
|---|---|---|
| Avantax Advisory Services, Inc. | 71,635 | $1.48M |
| First Horizon Advisors, Inc. | 625 | $12.9K |
| Atlas Capital Advisors LLC | 189 | $3.90K |